<DOC>
	<DOCNO>NCT01106157</DOCNO>
	<brief_summary>The primary purpose study determine give combination therapy consist Thymoglobulin® ( ATG ) Neulasta® ( GCSF ) patient establish Type 1 Diabetes ( T1D ) safe secondarily , ATG GCSF preserve insulin production .</brief_summary>
	<brief_title>Reversing Type 1 Diabetes After Established</brief_title>
	<detailed_description>This randomize , placebo control , phase I/II trial . Potential subject screen via 4 hour mixed meal tolerance test ass residual beta cell ( C-peptide ) function . If C-peptide level time ≥ 0.1 pmol/ml , subject meet additional inclusion exclusion criterion , eligible randomization enrollment . The study randomize 2:1 17 subject receive active therapy 8 receive placebo . Subjects must receive Thymoglobulin®/ Neulasta® placebo within 8 week randomization . Thymoglobulin® ( 2.5mg/kg ) /placebo give 0.5 mg/kg IV day 1 2 mg/kg day 2 . Six dos Neulasta® ( 6mg/dose ) /placebo give standard care every 2 week , first dose give prior discharge Thymoglobulin® infusion . Complete metabolic panel ( CMP ) complete blood count ( CBC ) do screen visit , prior study drug initiation , daily Thymoglobulin® infusion admission , follow visit . Following discharge , daily phone call make subject first 5 day therapy weekly thereafter . In addition , weekly phone call month follow completion therapy use document adverse reaction . Thereafter call make every two week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Must &gt; 12 year &lt; 45 Must diagnosis T1D great 4 month duration , upper limit 2 year , Now recruit diagnose great 1 year less 2 year . Must least one diabetesrelated autoantibody present ( e.g. , islet cell autoantigen ( ICA ) , GAD , ZnT8 , islet antigen 2 ( IA2 ) autoantibody ) Must stimulate Cpeptide level ≥ 0.1 pmol/ml ( 0.3ng/mL ) measure mixed meal tolerance test ( MMTT ) , conduct least 4 month diagnosis diabetes , within 8 week randomization Must EBV PCR negative within two week randomization EBV seronegative screening Be least 6 week last live immunization Be willing forgo live vaccine 3 month follow last dose study drug Be willing comply intensive diabetes management Normal screen value complete blood count ( CBC ) , renal function electrolyte ( CMP ) . Be immunodeficient clinically significant chronic lymphopenia : ( Leukopenia ( &lt; 3,000 leukocyte /μL ) , neutropenia ( &lt; 1,500 neutrophils/μL ) , lymphopenia ( &lt; 800 lymphocytes/μL ) , thrombocytopenia ( &lt; 125,000 platelets/μL ) . Have chronic infection time randomization Have positive PPD Be currently pregnant lactating , anticipate get pregnant within next two year Require use immunosuppressive agent Have serologic evidence current past HIV , Tuberculosis , Hepatitis B Hepatitis C infection Have complicate medical issue abnormal clinical laboratory result interfere study conduct , cause increase risk include preexist cardiac disease , chronic obstructive pulmonary disease ( COPD ) , sickle cell disease , neurological , blood count abnormality ( e.g. , lymphopenia , leukopenia , thrombocytopenia ) Have history malignancy Evidence liver dysfunction angiotensin sensitivity test ( AST ) ALT great 3 time upper limit normal Evidence renal dysfunction creatinine great 1.5 time upper limit normal Vaccination live virus within last 6 week Current use noninsulin pharmaceutical affect glycemic control Active participation another T1D treatment study previous 30 day Known allergy GCSF ATG Prior treatment ATG know allergy rabbit derived product Any condition investigator 's opinion , may adversely affect study participation may compromise study result</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Autoimmune , Diabetes Mellitus , Glucose Metabolism</keyword>
</DOC>